-
Home > About Us
About Us
-
Naurex Inc. is a clinical-stage company developing novel therapies for depression and other CNS disorders based on a new mechanism of action for modulating the N-methyl-D-aspartic acid receptor (NMDAR). Using these discoveries, Naurex researchers have generated novel chemical drug classes known as Glycine-site Functional Partial Agonists (GFPAs), which modulate the receptor in a different way than existing NMDAR agents. The company’s drug development programs based on its GFPA NMDAR modulators include the first-generation molecule, GLYX-13, the second-generation NRX-1050 small molecule series and additional compounds from Naurex’s platform of novel NMDAR modulators.
GLYX-13 is currently in Phase II clinical development as a therapy for treatment-resistant depression. In preclinical studies, it has shown promising signs of robust antidepressant activity with excellent safety. GLYX-13 has successfully completed a Phase I clinical trial demonstrating good safety in humans and it is now being studied in a Phase II proof-of-concept trial evaluating its use in patients who are not achieving adequate responses to their current antidepressant agents. The second-generation NRX-1050 series of compounds is advancing rapidly in preclinical development. Additional compounds in Naurex’s novel GFPA platform have potential in a number of other CNS disorders.